Less than 30% of FDA-cleared AI devices shared key safety and adverse event data before approval, raising regulatory concerns.
Key Details
- 1A new analysis reviewed FDA approval and recall databases for all AI/ML devices cleared from 1995 to July 2023.
- 2Of 691 devices analyzed, 531 targeted radiology applications.
- 3Fewer than 30% of devices provided data on safety, efficacy, or adverse events prior to approval.
- 4No predefined efficacy or safety reporting standards currently exist for AI/ML devices in the U.S., unlike with pharmaceuticals.
- 5The findings highlight a regulatory gap and call for stricter testing and dedicated approval pathways for AI/ML-based medical devices.
Why It Matters
This research underscores a major gap in regulatory standards and transparency for AI devices in radiology, potentially impacting patient safety and trust. Addressing these concerns could lead to more robust evidence and safer adoption of AI in clinical imaging practice.
Source
Radiology Business
Related News
•AuntMinnie
LLMs Demonstrate Strong Potential in Interventional Radiology Patient Education
DeepSeek-V3 and ChatGPT-4o excelled in accurately answering patient questions about interventional radiology procedures, suggesting LLMs' growing role in clinical communication.
•Radiology Business
Women's Uncertainty About AI in Breast Imaging May Limit Acceptance
Many women remain unclear about the role of AI in breast imaging, creating hesitation toward its adoption.
•AuntMinnie
Stanford Team Introduces Real-Time AI Safety Monitoring for Radiology
Stanford researchers introduced an ensemble monitoring model to provide real-time confidence assessments for FDA-cleared radiology AI tools.